Investors Research Corp Sells 11,121 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Investors Research Corp cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 96.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 415 shares of the biopharmaceutical company's stock after selling 11,121 shares during the period. Investors Research Corp's holdings in Gilead Sciences were worth $47,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences during the fourth quarter worth $31,000. Stephens Consulting LLC increased its holdings in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 260 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of Gilead Sciences in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on GILD shares. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Thursday, February 13th. The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Oppenheimer reduced their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Trading Up 0.4%

GILD stock traded up $0.42 during midday trading on Tuesday, hitting $109.33. The stock had a trading volume of 9,875,443 shares, compared to its average volume of 7,732,483. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market cap of $136.00 billion, a P/E ratio of 295.49, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The business has a fifty day moving average price of $105.49 and a two-hundred day moving average price of $101.04. Gilead Sciences, Inc. has a 1-year low of $62.69 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the company posted ($1.32) EPS. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.89%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,929 shares of company stock valued at $6,748,980. 0.27% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.